Silver is a precious metal that has been used for its antimicrobial properties for over 6,000 years — the ancient Egyptians used silver nitrate to prevent wound infections, the Romans stored water in silver vessels to keep it fresh, and silver coins were dropped into milk and other liquids to prevent spoilage. Before the discovery of antibiotics in the 20th century, silver was the primary antimicrobial agent available to medicine, and its use declined sharply with the introduction of the sulfonamides and penicillin. In recent decades, silver has experienced a renaissance as a topical antimicrobial agent, particularly in the form of silver sulfadiazine (the standard of care for burn wound dressing for over 50 years) and in the form of silver-impregnated catheters and other medical devices (where it reduces the risk of device-associated infections). The emergence of antibiotic-resistant bacteria has renewed interest in silver as an alternative antimicrobial agent, and research into the mechanisms of silver antimicrobial action has revealed multiple targets in bacterial cells that make it very difficult for bacteria to develop resistance.
Mechanisms of Antimicrobial Action
Silver exerts its antimicrobial effects through multiple mechanisms that collectively make it one of the most broad-spectrum and difficult-to-resist antimicrobial agents known. First, silver ions bind to the bacterial cell wall and disrupt its integrity — they bind to the lipopolysaccharide (LPS) layer of Gram-negative bacteria and to the peptidoglycan layer of Gram-positive bacteria, destabilising the cell wall and increasing its permeability. Second, silver ions bind to bacterial DNA and RNA, cross-linking the nucleic acid strands in a way that impairs DNA replication and RNA transcription. Third, silver ions bind to the sulfur-containing amino acids (cysteine and methionine) and to the sulfur-containing enzymes that are essential for bacterial energy metabolism — including the iron-sulfur cluster-containing enzymes of the electron transport chain, which are highly sensitive to silver-induced inactivation. Fourth, silver ions generate reactive oxygen species (including superoxide, hydrogen peroxide, and the hydroxyl radical) that cause additional oxidative damage to bacterial proteins, lipids, and DNA. This multi-target mechanism makes silver simultaneously effective against bacteria, fungi, viruses, and protozoa — and makes it very difficult for any of these pathogens to develop clinically significant resistance to silver.
The emergence of silver resistance is a growing concern. While true silver resistance is still rare in clinical isolates, laboratory studies have demonstrated that bacteria can develop resistance to silver through multiple mechanisms — including efflux pumps that export silver ions from the bacterial cell, metallothionein-like proteins that sequester silver ions, and reduced uptake of silver due to changes in the cell wall. The clinical significance of these resistance mechanisms is not yet clear, but they underscore the importance of using silver as part of a combination therapy (rather than as a monotherapy) when possible, to reduce the selective pressure for silver resistance development.
Clinical Evidence
The clinical evidence for silver in wound care is strong and well-established. Silver sulfadiazine (SSD, 1% cream) has been the standard of care for burn wound dressing for over 50 years, based on extensive clinical experience showing that it reduces wound infection rates, accelerates wound healing in infected burns, and is safe for use in large burn surface areas. A meta-analysis of 26 trials in burn patients found that silver sulfadiazine was associated with a significant reduction in wound infection rates compared to non-silver dressings, with no significant difference in wound healing time or in overall mortality. More recent evidence suggests that the efficacy of silver sulfadiazine is primarily apparent in wounds that are already infected — for uninfected burn wounds, the evidence for a benefit of silver over non-silver dressings is less clear, and the cost differential is substantial. Silver-impregnated catheters (for central venous catheters, urinary catheters, and endotracheal tubes) have been shown in multiple trials to reduce the incidence of device-associated infections, though the magnitude of the benefit varies by device type and clinical setting.
Practical Application
For general wound care, the evidence-based use of silver is in the topical treatment of infected wounds, burn wounds, and chronic wounds (pressure ulcers, venous leg ulcers) that are at risk of infection or that have failed to respond to standard wound care. Silver sulfadiazine (SSD) cream is applied to the wound in a thin layer (1-2mm) once or twice daily under sterile technique, with a non-adherent dressing. Silver-impregnated dressings (such as Aquacel Ag, Acticoat, and Mepilex Ag) provide sustained silver release over multiple days and are used for the management of colonised or infected chronic wounds. The primary adverse effect of topical silver is argyria (a permanent blue-gray discoloration of the skin and mucous membranes from silver deposition) with prolonged high-dose use, though this is rare with modern silver preparations and is not a risk with topical use. For comprehensive wound care, silver pairs well with the basic principles of moist wound healing (appropriate dressings, debridement, infection control), zinc (for immune function and collagen synthesis), vitamin C (for collagen synthesis), and protein supplementation (for the synthesis of the extracellular matrix proteins that constitute granulation tissue).
Leave a Reply